Daniel S Freeman

US Patent:

20220211847, Jul 7, 2022

Filed:

May 6, 2020

Appl. No.:

17/609002

Inventors:

- CAMBRIDGE, CAMBRIDGESHIRE, GB
- MARSEILLE, FR
DANIEL J. FREEMAN - GAITHERSBURG MD, US

International Classification:

A61K 39/395
A61K 31/519
A61K 31/513
A61K 31/282
A61P 35/00

Abstract:

The disclosure relates to methods and compositions for the treatment of cancer. Specifically, the disclosure relates to methods comprising administering to a subject in need thereof for the treatment of cancer a NKG2A neutralizing agent, a PD-1 neutralizing agent, a chemotherapy agent, and a VEGF neutralizing agent or an EGFR neutralizing agent.

US Patent:

20200199567, Jun 25, 2020

Filed:

Dec 18, 2019

Appl. No.:

16/718920

Inventors:

- Gaithersburg MD, US
JOHN MUMM - GAITHERSBURG MD, US
DANIEL J. FREEMAN - GAITHERSBURG MD, US
JINLIN JIANG - GAITHERSBURG MD, US
SOMEET NARANG - GAITHERSBURG MD, US
RONALD HERBST - GAITHERSBURG MD, US
DANIELLE TOWNSLEY - GAITHERSBURG MD, US
GIANLUCA CARLESSO - GAITHERSBURG MD, US
TAEIL KIM - GAITHERSBURG MD, US

International Classification:

C12N 13/00
C12N 5/0783
G01N 33/543
A61K 35/17
A61K 39/395

Abstract:

The disclosure provides methods for the selection and isolation of T cells expressing programmed cell death 1 (PD-1) and for selecting a PD-1 expression level of the isolated PD-1 expressing T cells. The disclosure also provides methods of large scale expansion of selected and isolated PD-1 expressing T cells, as well as methods for treating a subject comprising administering selected and isolated PD-1 expressing T cells to the subject.

US Patent:

20200140954, May 7, 2020

Filed:

Aug 21, 2019

Appl. No.:

16/547434

Inventors:

- Tokyo, JP
- Martinsried, DE
- Thousand Oaks CA, US
Daniel J. FREEMAN - Holmdel NJ, US
Robert Allen BECKMAN - Blue Bell PA, US
Xiaoping JIN - Hillsborough NJ, US

Assignee:

Daiichi Sankyo Co., Ltd. - Tokyo
U3 Pharma GmbH - Martinsried
AMGEN, INC. - Thousand Oaks CA

International Classification:

C12Q 1/6886
C07K 16/32
C07K 16/28
A61K 39/395
A61K 45/06

Abstract:

The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as low.

US Patent:

20170166973, Jun 15, 2017

Filed:

Oct 19, 2016

Appl. No.:

15/297775

Inventors:

- Tokyo, JP
- Martinsried,, DE
- Thousand Oaks CA, US
Daniel J. FREEMAN - Holmdel NJ, US
Robert Allen BECKMAN - Blue Bell PA, US
Xiaoping JIN - Hillsborough NJ, US

Assignee:

Daiichi Sankyo Co., Ltd. - Tokyo,
U3 Pharma GmbH - Martinsried,
AMGEN, Inc. - Thousand Oaks CA

International Classification:

C12Q 1/68
A61K 39/395
A61K 45/06
C07K 16/32

Abstract:

The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as low.

US Patent:

20150152508, Jun 4, 2015

Filed:

Sep 30, 2014

Appl. No.:

14/502792

Inventors:

- Tokyo, JP
- Martinsried, DE
Daniel J. FREEMAN - Holmdel NJ, US
Robert Allen BECKMAN - Blue Bell PA, US
Xiaoping JIN - Hillsborough NJ, US

Assignee:

Daiichi Sankyo Company, Limited - Tokyo
U3 Pharma GmbH - Martinsried

International Classification:

C12Q 1/68
C07K 16/28

Abstract:

The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as low.

US Patent:

20150147326, May 28, 2015

Filed:

Sep 30, 2014

Appl. No.:

14/502769

Inventors:

- Tokyo, JP
- Martinsried, DE
- Osaka, JP
Daniel J. FREEMAN - Holmdel NJ, US
Robert Allen BECKMAN - Blue Bell PA, US
Xiaoping JIN - Hillsborough NJ, US
Kimio YONESAKA - Osakasayama City, JP
Kazuhiko NAKAGAWA - Osakasayama City, JP

Assignee:

Daiichi Sankyo Company, Limited - Tokyo
U3 Pharma GmbH - Martinsried
Kinki University - Osaka

International Classification:

G01N 33/574
C07K 16/40
A61N 5/10
A61K 31/517
A61K 45/06
C07K 16/28
A61K 39/395

US Classification:

4241361, 4241581, 4241421, 4241331, 435 29, 436501, 435 71, 435 792, 435 794, 435 772, 600 1

Abstract:

The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as low. The invention is also directed to methods of performing an ELISA, including sequential steps of contacting a solid surface with a plurality of solutions each comprising in turn a capture antibody, a blocking agent, a sample suspected of containing an analyte, a detection antibody and an enzyme conjugate, in which the solid surface is subjected to a wash process after each sequential step.